Biopharmx (BPMX) Stock Price Down 9.1%

Biopharmx Corp (NYSEAMERICAN:BPMX) shares fell 9.1% on Wednesday . The stock traded as low as $0.10 and last traded at $0.10. 2,550,151 shares changed hands during mid-day trading, an increase of 64% from the average session volume of 1,556,003 shares. The stock had previously closed at $0.11.

Several brokerages recently weighed in on BPMX. Maxim Group reaffirmed a “buy” rating and issued a $1.50 target price (down from $3.00) on shares of Biopharmx in a research report on Wednesday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Biopharmx in a research report on Tuesday, September 19th.

In related news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total value of $59,278.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen Morlock purchased 330,000 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was bought at an average price of $0.15 per share, with a total value of $49,500.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY WARNING: “Biopharmx (BPMX) Stock Price Down 9.1%” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/22/biopharmx-bpmx-stock-price-down-9-1.html.

Biopharmx Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit